Transcription Strikes Back: Clinical Utility of Lung Adenocarcinoma Subtypes

Using transcriptional profiling, three robust subtypes of nonsquamous non-small cell lung cancer were defined, independently of initiating oncogenic driver events. Subtype-specific differential sensitivity to MEK 1/2 inhibitors was reported and an interaction between the mucinous subtype, STKII/LKBI genomic alterations, and inferior clinical outcomes with atezolizumab in the OAK clinical trial was identified.

Automated summary

Transcriptional profiling identified three robust subtypes of nonsquamous non-small cell lung cancer, regardless of initiating oncogenic driver events. Differential sensitivity to MEK 1/2 inhibitors was reported among the subtypes, and an interaction involving the mucinous subtype, STKII/LKBI genomic alterations, and inferior clinical outcomes with atezolizumab in the OAK clinical trial was identified.